These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 8719046)

  • 1. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
    Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 3. Parallel double-blind study of pergolide in Parkinson's disease.
    Jankovic J; Orman J
    Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
    [No Abstract]   [Full Text] [Related]  

  • 4. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 6. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease with pergolide: a double-blind study.
    Ahlskog JE; Muenter MD
    Mayo Clin Proc; 1988 Oct; 63(10):969-78. PubMed ID: 3050300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of early Parkinson's disease: are complicated strategies justified?
    Ahlskog JE
    Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pergolide: long-term use in Parkinson's disease.
    Ahlskog JE; Muenter MD
    Mayo Clin Proc; 1988 Oct; 63(10):979-87. PubMed ID: 3050301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients.
    Earley CJ; Allen RP
    Sleep; 1996 Dec; 19(10):801-10. PubMed ID: 9085489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
    Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG
    Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
    Koller W; Lees A; Doder M; Hely M;
    Mov Disord; 2001 Sep; 16(5):858-66. PubMed ID: 11746615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 17. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 19. [Management of complications related to intraduodenal infusion of levodopa/carbidopa in patients with Parkinson's disease].
    Santos-Garcia D; de Deus T; Lopez-Pazos E; Macias-Arribi M; Llaneza-Gonzalez MA; Echarri-Piudo A; Carpintero P; de la Fuente-Fernandez R
    Rev Neurol; 2014 Jun; 58(11):505-15. PubMed ID: 24861226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pergolide in Parkinson's disease].
    Parkes D
    Arch Neurobiol (Madr); 1991; 54(6):288-95. PubMed ID: 1811459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.